Loss deepens sharply. BioNTech SE reported an adjusted loss of -$1.25 per share for Q4 2025, matching the prior quarter’s loss of $0.33 but swinging from a profit of $1.08 per share in Q4 2024. The biotech posted a net loss of $305 million for the quarter, reflecting the sharp year-over-year reversal as COVID-19 vaccine revenue continues to normalize.
Revenue slides 23.8%. Quarterly revenue of $907.4 million declined 23.8% from $1.19 billion in the year-ago quarter, though it matched the prior quarter’s $907.4 million. The year-over-year contraction underscores the ongoing headwinds facing the company’s core vaccine franchise as pandemic-era demand fades. Trading volume reached 1.03 million shares as the stock held steady at $101.50.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.